What is Chardan Capital’s Forecast for XENE FY2025 Earnings?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Investment analysts at Chardan Capital issued their FY2025 earnings estimates for Xenon Pharmaceuticals in a research report issued on Wednesday, November 19th. Chardan Capital analyst K. Nakae expects that the biopharmaceutical company will post earnings per share of ($4.30) for the year. Chardan Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Chardan Capital also issued estimates for Xenon Pharmaceuticals’ FY2026 earnings at ($2.15) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.01. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.81) EPS.

Several other brokerages have also recently commented on XENE. JPMorgan Chase & Co. boosted their price target on Xenon Pharmaceuticals from $57.00 to $60.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Wedbush upped their target price on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an “outperform” rating in a report on Tuesday, August 12th. Needham & Company LLC reissued a “buy” rating and issued a $55.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Tuesday, October 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Tuesday, October 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $54.27.

Xenon Pharmaceuticals Trading Up 2.2%

NASDAQ:XENE opened at $42.05 on Monday. The stock has a 50 day moving average of $39.93 and a two-hundred day moving average of $35.69. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $44.23. The firm has a market cap of $3.25 billion, a P/E ratio of -11.85 and a beta of 1.10.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC acquired a new position in shares of Xenon Pharmaceuticals in the 2nd quarter valued at $25,000. Danske Bank A S purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals in the first quarter valued at about $30,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at about $39,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at about $32,000. Institutional investors and hedge funds own 95.45% of the company’s stock.

Insider Activity

In other news, CEO Ian Mortimer sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $40.16, for a total transaction of $1,004,000.00. Following the completion of the sale, the chief executive officer owned 31,302 shares in the company, valued at $1,257,088.32. This trade represents a 44.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.07% of the stock is owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.